Navigation Links
One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
Date:3/19/2008

Although Two-Thirds of Surveyed Physicians Anticipate an Increase in the Number of Patients Treated for Low HDL Over the Next Two years, 19 Percent

of Surveyed MCOs Will Not Add Novel HDL Drugs to Their Formularies,

According to a New Report from Decision Resources

WALTHAM, Mass., March 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that approximately one-third of surveyed primary care physicians (PCPs) and cardiologists do not consider it necessary to treat low high- density lipoprotein (HDL) until patients' HDL levels drop below the recommended threshold established by the U.S. National Cholesterol Education Program's Adult Treatment Panel III guidelines.

The new Physician & Payer Forum primary market research report entitled Are Payers and Physicians Ready for a Paradigm Shift in Preventive Cardiology? An Assessment of Current and Future Use of HDL-Targeting Therapies finds that most surveyed PCPs and cardiologists anticipate that the number of patients treated for low HDL will increase due to the launch of new HDL-raising therapies. These drugs, which offer improved tolerability and/or efficacy compared with currently available agents, include Merck's Cordaptive, Merck's MK-0524B and novel agents such as Merck's anacetrapib and Roche's dalcetrapib. However, 19 percent of surveyed managed care organizations' (MCOs) pharmacy directors said that they would not add any novel HDL drug to their private plan formularies. The report finds that MCOs have lower efficacy expectations than physicians do for new HDL-raising therapies and are more willing to trade off improvements in efficacy in return for treatments that offer better safety and tolerability.

"MCO pharmacy directors say that the most important key factors that would affect their willingness to include a novel HDL-raising therapy into their private plan formularies include outcomes data, low cost and efficacy in reducing low-density lipoprotein (LDL) cholesterol or high triglycerides in addition to raising HDL," said Donny Wong, Ph.D., principal analyst at Decision Resources. "Drug companies are unlikely to get good formulary tier placement for novel HDL therapies on the basis of improved tolerability alone."

Are Payers and Physicians Ready for a Paradigm Shift in Preventive Cardiology? An Assessment of Current and Future Use of HDL-Targeting Therapies is based on a U.S. survey of 73 U.S. cardiologists, 73 PCPs, and 21 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About High-Density Lipoprotein Cholesterol

Patients with low levels of HDL cholesterol are at elevated risk for cardiovascular disease, even if their levels of LDL cholesterol are well controlled. An estimated 50 percent of cardiovascular events occur in patients with low HDL, an under-treated disorder that afflicts nearly 30 million individuals in the United States. In 2007, agents that target low HDL achieved less than $800 million in sales, compared with close to $8 billion achieved by statins targeting high LDL.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
2. Acute lung injury patients one-third less likely to die in closed model ICUs
3. Over one-third of former American football players had sexual relations with men, study says
4. One-Third of Popular Songs Refer to Substance Abuse
5. New Gallup Survey Finds Half of Los Angeles Area Residents Have Taken in a Near-Homeless Person, One-Third Fear Homelessness Themselves
6. AIDS Ignorance: One-Third of Adults Admit Little or No Knowledge of Pandemic
7. One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC
8. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
9. Kaiser Permanente Study Shows One-Third of Women Have Overactive Bladder, Incontinence or Other Pelvic Floor Disorders
10. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
11. Study finds primary care depression treatment often does not follow quality guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
(Date:6/23/2016)... -- The National Pharmaceutical Council (NPC) today announced that ... organization as its newest member.  ... and chief scientific officer, Mallinckrodt Pharmaceuticals, will serve ... of Directors. ... in support of our efforts to conduct research ...
Breaking Medicine Technology: